Kornimate/medical-research-clean huggingface dataset:
marathon of hope cancer centres network study for ontario (mohccn-o)

Conditions: Breast Cancer; Colorectal Cancer; Pancreas Cancer; Kidney Cancer; Prostate Cancer; Ovary Cancer; Head and Neck Cancer; Leukemia; Lymphoma; Lung Cancer; Melanoma; Solid Tumor

Summary: the marathon of hope cancer centres network (mohccn) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in dna, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

the purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. approximately 15,000 participants will take part in the greater mohccn study across canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Eligibility criteria:
inclusion criteria: 1. patients with histological and/or cytological confirmation of blood or solid tumor malignancies. for tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy 2. all patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: 1. already existing data that satisfies the minimal requirements of a gold standard case (refer to table 1) 2. have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization 3. patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived formalin-fixed paraffin-embedded (ffpe) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling. 4. participating patients must agree to share their anonymized clinical and genomic data exclusion criteria: none.
cross iron (comparative randomized oral versus systemic iron)

Conditions: Allogenic Transfusion; Perioperative Anaemia; Knee Arthroplasty; Hip Arthroplasty

Summary: patients were recruited at the scheduled preoperative visit for hip or knee arthroplasty. if the haemoglobin (hb) level was below 13 g/dl with no contraindication to iron supplementation the patients were randomized to the oral or intravenous (iv) group. the oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (epo) injections (40 000 iu subcutaneous on day - 21, day - 14 and day-7). the iv group received ferric carboxymaltose 1000 mg iv in 15 minutes one month before surgery, associated with 3 epo injections. primary efficacy endpoint was the change in hb level from the day of the preoperative visit to the day before surgery (day-1). secondary endpoints comprised the hb level on day 3 and 5 after surgery, allogenic transfusion during and after surgery, and the change in iron indices from the day of the preoperative visit to day - 1.


Eligibility criteria:
inclusion criteria: * unilateral prothetic orthopaedic surgery scheduled * age \> 18 * weight \> 50 kg * hemoglobin rate: 10 g/dl ≤ hb \<13 g/dl exclusion criteria: * bilateral arthroplasty * epo contraindication * generalized infection

Keywords: anaemia iron deficiency ferric carboxymaltose patient blood management hip arthroplasty knee arthroplasty
fluid shifts in patients treated with therapeutic hypothermia after cardiac arrest

Conditions: Cardiac Arrest

Summary: therapeutic hypothermia after cardiac arrest har shown to improve the rate of survival in a significant way. however hypothermia also causes leak of fluid into the surrounding tissue. this edema could lead to damage to the same tissue, not beneficial for the patients. we therefore try to evaluate if hyperosmolar, hyperoncotic fluid as an alternative to std. treatment (nacl/ra)could affect the edema in a positive way, and result to a better outcome neurological for the patients.

after the patients are admitted to our hospital we randomise them to either std. fluid therapy (nacl/ra) or hyperhaes. after pci we state the rate of cerebral edema by carrying out a cerebral mri before the cooling starts. we treat the patients with the different fluids for 24 hours. we then evaluate the edema after 24 and 72 hours by the same method. in addition we state the rate of peripheral capillary leak by wick's method. the capillary leak is calculated every 8.th hour for the 1. day the patients are treated in our icu. after 1 year, those who survive are invited to a follow-up where we test the patient using mini mental status, sf-36, in addition to neurophysiological tests as eeg and the p300-test. we then relate the results to the fluid given initially after the cardiac arrest.

Eligibility criteria:
inclusion criteria: * witnessed cardiac arrest, * als started within 15 min. * rosc within 60 min. * still unconscious, * age 18-80 exclusion criteria: * other malignancies, * persons who wake up, * pregnancy

Keywords: cardiac arrest hypothermia neurologic outcome edema
stepping to understand lower limb impairments in bilateral cerebral palsy

Conditions: Cerebral Palsy; Bilateral Cerebral Palsy; Diplegic Cerebral Palsy

Summary: the purpose of this study is to investigate lower limb impairments in children with bilateral cerebral palsy during stepping tasks.

individuals with bilateral cerebral palsy (bcp) sustain a neonatal brain injury that leads to altered neuromuscular control to the lower limbs. one commonly observed motor impairment from this altered control is loss of selective voluntary motor control (svmc), defined as the ability to independently move the joints intentionally. loss of svmc typically manifests as knee and ankle joint impairment and abnormal coupling between the hip adductors and lower limb extensors. this can make stepping up or down a curb or stair challenging, but quantitative investigation in these closed-chain activities has been limited. this is especially important as performance in stair-climbing is associated with limitations to overall mobility and community participation in cerebral palsy. the overall aim of this proposal is to investigate the altered neuromuscular control that challenges stair walking in individuals with bcp. participants who consent to the study will be instructed to perform multiple step-ups and step-downs on a single raised platform. the parameters of the stepping task may change by adding weight to the body or subtracting weight from the body. using standard gait analysis techniques, biomechanical metrics such as joint kinematics and kinetics will be analyzed.

Eligibility criteria:
inclusion criteria: * aged 5 years to 19 years * typically developing with no diagnosed medical conditions that affect movement, or with a diagnosis of bilateral cerebral palsy (including diplegia, tetraplegia, and quadriplegia) where the lower limbs are more affected than the upper limbs * ability to independently step up, with or without assistive devices. exclusion criteria: * lower limb surgery in the past year * botulinum toxin injections to the lower limb muscles in the past 6 months * cognitive dysfunction that would make following directions difficult * comorbidities that would make participation unsafe.

Keywords: cerebral palsy bilateral cerebral palsy gait stepping stairs biomechanics neuroscience
soy protein and breast cancer risk reduction

Conditions: Breast Cancer

Summary: soy consumption has been associated with reduced risk for developing breast cancer. ovarian hormones and breast density are considered breast cancer risk markers. we propose to test the hypothesis that consumption of soy protein reduces ovarian steroid hormones and results in a corresponding reduction in breast density comparing to casein protein.

the aims will be tested by conducting a randomized, double-blind study, with two arms and 100 women in each arm. premenopausal women will be recruited and randomly allocated to take one of two different dietary supplements daily for 2 years. the two test diets soy protein drink and caseinate protein drink. multiple blood, urine, and breast fluid samples will be obtained before and during the dietary intervention period and analyzed for ovarian hormones. at baseline and after the intervention period, breast density, and bone density will be assessed by radiological techniques at baseline and 1 yr and 2 yr after protein drink supplementation. the efficacy of the dietary intervention will be determined by comparing mean changes of ovarian steroids, and density of the breast and bone tissues over the 2 year dietary intervention period in the two diet groups with adjustment for baseline values and individual patient characteristics of interest. we predict that 2 years of soya dietary supplements will reduce breast density, which will be explained by individual hormonal changes.

Eligibility criteria:
inclusion criteria: * healthy premenopausal women * 30 to 40 years old * normal mammograms * regular menstrual cycles exclusion criteria: * abnormal mammograms * first degree relatives with breast cancer * pregnant or lactating * peri- or post-menopause * breast augmentation, reduction, and lifting * on oral contraceptive medications or exogenous hormones * medically prescribed diets * allergic reaction to soy or cow's milk

Keywords: soy diet breast cancer ovarian hormones breast density prevention
the effects of iron and omega-3 fatty acid supplementation on cognition and immune function in iron deficient children

Conditions: Iron Deficiency; Anemia

Summary: the aim of this study is to determine if providing iron and a mixture of dha and epa, alone and in combination, to children with iron deficiency and poor n-3 fatty acid intake will improve their cognitive performance, activity levels and immune system. additionally, the effects on iron and fatty acid status, and gut microbiota, will be assessed.

in populations of low socio economic status, such as found in south africa, iron deficiency coexisting with a low intake of n-3 fatty acids could synergistically compromise both the intellectual performance and immune system of children. therefore, specific cognitive processes (domains) and specific immunization status markers and immune function modulators, that have been found to be affected by iron and n-3 fatty acid deficiency in children in previous studies will be assessed. this will be the first human study that assesses the interactions of iron and n-3 fatty acid supplementation to iron deficient children in a two-by-two factorial, randomized, double-blind, placebo-controlled trial.

Eligibility criteria:
inclusion criteria: * age: 6-10 years * iron deficiency (serum ferritin \ 70 µmol/mol heme in washed erythrocytes or tfr \> 8.3 mg/l) with no or mild anaemia exclusion criteria: * chronic illness * severe anemia (hb \< 80 g/l) * use of iron or n-3 fatty acid containing supplements
quickflex micro left ventricular lead post approval study

Conditions: Heart Failure

Summary: the purpose of this multicenter post-approval study is to evaluate the acute and chronic performance of the quickflex® μ 1258t left ventricular (lv) lead.

the primary endpoints of the study are: * freedom from lv lead-related complications at 5 years * lv bipolar capture threshold of st. jude medical's quickflex®µ 1258t lv lead measured at 0.5 ms at 5 years

Eligibility criteria:
inclusion criteria: * have an approved indication per american college of cardiology/american heart association/heart rhythm society guidelines for implantation of a crt-d system or participated in the quickflex® μ1258t (investigational device exemption (ide) study * have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations exclusion criteria: * have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate or short term contact with heparin * have a life expectancy of less than 5 years due to any condition * be less than 18 years of age

Keywords: left heart pacing lead cardiac resynchronization therapy (crt) heart failure
optimised procedure in patients with nstemi and ckd

Conditions: Non-ST-segment Elevation Myocardial Infarction; Chronic Kidney Disease

Summary: aim of the study is the determination of the ideal timepoint for the treatment of patients with acute non-st-segment elevation myocardial infarction (nstemi) and an acute or chronic kidney disease (ckd) with a grace score \< 140. it should be determine if a prompt coronary angiography or the protection of the kidneys from the used contrast agent is more important for the outcome of the patients. additionally it will be investigated if the ischemic precondition can help to prevent heart damages.

according to international guidelines a coronary angiography has to be performed within 72h for patients with (nstemi). patients with a grace score \> 140 belong to the high risk group and the coronary angiography has to be performed within 24h. until today for patients with a grace score \> 140 and an acute or chronic kidney disease (ckd) the best approach is not known even though up to 40% of all nestmi patients belong to this population. ckd in connection with an nstemi is one predictor for short and long term mortality and serious bleeding as a complication of coronary angiography. additionally patient with ckd are at risk to experience a contrast agent induced aggravation of the ckd right up to a kidney failure. the pre- and post treatment of the kidneys seem to reduce this risk. the irrigation of the kidneys up to 48h prior coronary angiography optimises the kidney function and buffers the aggravation of kidney function caused by fluid loss or abstention at home. additionally the influence of ischemic precondition on one arm of the patient will be evaluated in this setting. first studies give a hint that the kidneys may be protected against the contrast agent of the following catheter examination by ischemic precondition.

Eligibility criteria:
inclusion criteria: * patient with an acute nstemi * patient with a grace score \< 140 * patient with an acute or a chronic kidney disease (stage 1 - 5) * patient who agree with the randomized assignment to one of the study groups in written * signed informed content prior to study inclusion * patient who are legally competent at the time of study inclusion exclusion criteria: * pregnancy * nursing women * patient has been committed to an institution by legal or regulatory order * mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study * participation in a parallel clinical trial * subjects who are in any state of dependency to the investigators

Keywords: nstemi, ckd
evaluation of electronic florbetapir (18f) interpretation training in japanese physicians

Conditions: Alzheimer's Disease

Summary: this study is designed to validate the japanese electronic florbetapir (18f) interpretation training program intended for post-approval implementation in japan.


Eligibility criteria:
inclusion criteria: * japanese society of nuclear medicine (jsnm) positron emission tomography (pet) certified nuclear medicine physician * minimal hands-on experience and no formal training in the visual interpretation of florbetapir (18f) brain pet scans * minimal hands-on experience and no formal training in the quantitation of florbetapir (18f) brain pet scans exclusion criteria: * prior hands-on experience or formal training in the visual interpretation and/or quantitation of florbetapir (18f) pet scans
spinal cord stimulation for orthostatic hypotension

Conditions: Orthostatic Hypotension

Summary: this is a prospective single-center randomized crossover control study that aims to evaluate the effects of non-invasive transcutaneous spinal cord stimulation in patients with known or suspected orthostatic hypotension.

the hypothesis is that transcutaneous spinal cord stimulation at thoracic level may correct hypotensive episodes during tilt testing in subjects with blood pressure drops. eligible patients will sign an informed consent form before the procedure. non-invasive transcutaneous electrical stimulation of the spinal cord will be applied using modulated electrical impulses through external adhesive electrode patches connected to a neural stimulator device. the study protocol includes analysis of the following parameters: heart rate; 12-lead electrocardiogram; continuous beat-to-beat blood pressure recordings (measured noninvasively by plethysmography) before stimulation, during stimulation and after spinal cord stimulation. all registered data will be analyzed at the end of the procedure.

Eligibility criteria:
inclusion criteria: 1. age 18-85 years 2. suspected orthostatic hypotension (having a history of syncope and/or pre-syncope that occurred during the transition to an upright position, with complaints of recurrent dizziness that occurs during the transition to an upright position) or documented orthostatic hypotension. 3. the patient who signed the informed consent form exclusion criteria: 1. orthostatic hypotension caused by acute hypovolemia or bleeding. 2. chronic heart failure iii-iv functional class (nyha) 3. structural heart disease of the following: hypertrophic cardiomyopathy with obstruction of the left ventricular outflow tract, acute coronary syndrome, restrictive cardiomyopathy, hemodynamically significant valvular heart defects, uncorrected hemodynamically significant congenital heart defects. 4. ongoing acute illness. 5. \>90% paced cardiac rhythm. 6. permanent atrial fibrillation. 7. a history of transient ischemic attack or stroke within 3 months before the enrollment and/or incomplete recovery. 8. pulmonary embolism \<1 month ago. 9. epilepsy. 10. the presence of an implantable pump. 11. patients with contraindications to the use of the patch electrodes used in this study, as indicated in the relevant instructions for use.

Keywords: spinal cord stimulation hypotension hemodynamic effects
using technology to improve physical activity levels among postmenopausal women (the active & aware study)

Conditions: Breast Cancer

Summary: women who are overweight or do not exercise are at higher risk for breast cancer after menopause. this study will test a new electronic device that measures the body's movement and works alongside a website to help women increase their physical activity level. if effective, this system could be tested in larger studies aiming to reduce breast cancer risk by reducing or preventing obesity.


Eligibility criteria:
inclusion criteria: * female * postmenopausal * bmi \>= 25.0 kg/m2 * physically inactive * internet user with regular access to high-speed internet * willing and able to complete study requirements exclusion criteria: * history of invasive breast cancer * medical contraindication to exercise * medical problem or other issue that would interfere with intervention * current participation in another physical activity study

Keywords: primary prevention sedentary overweight obesity breast cancer post-menopausal women
mometasone furoate nasal spray in italian children

Conditions: Rhinitis, Allergic; Nasal Allergy; Allergy Pollen; Nasal, Cytology; Mometasone Allergy; Quality of Life; Child, Only

Summary: objective seasonal allergic rhinitis (sar) is a common disease in childhood and characterized by type 2 inflammation, bothersome symptoms, and impaired quality of life (qol). intranasal corticosteroids are effective medications in managing sar patients. in addition, mometasone furoate nasal spray (mfns) is a well-known therapeutic option. however, the literature provided no data about its effects in european children with sar. thus this study addressed this unmet need.

objective seasonal allergic rhinitis (sar) is a common disease in childhood and characterized by type 2 inflammation, bothersome symptoms, and impaired quality of life (qol). intranasal corticosteroids are effective medications in managing sar patients. in addition, mometasone furoate nasal spray (mfns) is a well-known therapeutic option. however, the literature provided no data about its effects in european children with sar. thus this study addressed this unmet need. methods mfns was compared to isotonic saline. both treatments were prescribed one spray per nostril, twice a day, per 3 weeks. nasal cytology, total symptom score (tss), visual analogic scale concerning the parental perception of symptom severity, and the pediatric rhinoconjunctivitis quality of life questionnaire (prqlq) were assessed at baseline, after 7 and 21 days, and one month after discontinuation.

Eligibility criteria:
inclusion criteria: * inclusion criteria were: age range 4-12 years, sar diagnosis, total symptoms score (tss) ≥ 6, and written informed consent of both parents or legal guardians. exclusion criteria: * exclusion criteria were: perennial ar, rhinitis due to other causes, concomitant acute or chronic rhinosinusitis, nasal polyps, asthma comorbidity, current use of topical or systemic corticosteroids, antihistamines, antileukotrienes, inadequate washout of them, nasal anatomic defect, respiratory infections in the last two weeks, participation in other clinical studies in the previous month, documented hypersensitivity to the study product or its excipients, and trip planned outside of the study area.

Keywords: seasonal allergic rhinitis mometasone furoate nasal spray nasal cytology type 2 inflammation symptoms quality of life